Varlitinib

Drug Profile

Varlitinib

Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370; Varlitinib tosylate

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; ASLAN Pharmaceuticals
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer; Cholangiocarcinoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer
  • Phase II/III Gastric cancer
  • Phase II Breast cancer; Cholangiocarcinoma
  • Phase I Solid tumours
  • Clinical Phase Unknown Hepatocellular carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in Singapore (PO, Tablet)
  • 07 Sep 2017 Clinical trials in Hepatocellular carcinoma (Metastatic disease, Late-stage disease) in Singapore (PO)
  • 16 Aug 2017 ASLAN Pharmaceuticals enters into a research collaboration agreement with Academia Sinica for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top